Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Quattroflow™ Introduces 5050 Series Quaternary Diaphragm Pumps

Published: Tuesday, May 14, 2013
Last Updated: Tuesday, May 14, 2013
Bookmark and Share
Ideal for use in demanding biotech and pharmaceutical applications.

Quattroflow™ has announced the introduction of its 5050 Series Quaternary Diaphragm Pump to its family of biotech and pharmaceutical pumps.

This innovative pump system features compact dimensions, multi-directional connections and the ability to satisfy a wide variety of flow-rate requirements, which makes it ideal for use in demanding biotech and pharmaceutical applications.

The 5050 pump provides multi-option installation flexibility and a compact design. The unit is drainable and cleanable, and includes multi-directional pump-head connections and positioning.

The 5050 pump features a 225mm (8.86”) chamber diameter and 50mm (1-1/2”) flange porting.

The 5050 pump has a wide flow range from 50 to 5,000 L/hr (13 to 1,321 gph), with maximum pressure to 6 bar at 20°C (87 psi at 68°F). The complete flow range can be achieved with one drive, no further drive options needed.

The pump chamber is available in 316L stainless steel for multiple-use and polypropylene (PP) for single-use applications. The pump’s valves are constructed of EPDM, while the diaphragm is Santoprene® (EPDM/PP compound).

Quattroflow’s positive displacement pumps incorporate a four piston-diaphragm technology with no mechanical seals that is driven by an eccentric shaft and motor.

Quattroflow products primarily serve the biotech and pharmaceutical industries that require gentle displacement, reliability, product safety, purity and cleanability.

The 5050 pump can be found in multiple or single-use applications within cross-flow systems, chromatography devices and centrifuges.

Quattroflow is a leading brand from Almatec, which is part of Dover Corporation’s Pump Solutions Group (PSG®).


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Antibody Drug Shows Promise in HIV Treatment
Researchers are a step closer to an alternative HIV treatment that has the potential for lasting effects and less frequent dosing.
Flu Vaccine May Reduce Risk of Death For Type 2 Diabetes Patients
Researchers at Imperial College London have suggested that the vaccine may have substantial benefits for patients with long-term conditions.
Flu Vaccine May Reduce Death Risk of Type 2 Diabetes
New research suggests that a new flu vaccine may reduce probability of type 2 diabetes patients being hospitalised with stroke and heart failure.
Disrupting Tumour-Promotion in Humans
Researchers have modified an existing protein to represses a specific cancer-promoting ‘message’ within cells.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Vaccine Strategy Targets Multiple Influenza Viruses
Scientists have identified vaccine-induced antibodies that can neutralize strains of influenza virus that infect humans.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Structure of Cold Virus Solved
Researchers have identified the structure of an elusive cold virus linked to child asthma and respiratory infections, providing the foundation for treating the virus.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!